INSM - Insmed Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
27.07
+0.97 (+3.72%)
At close: 4:00PM EST

27.07 0.00 (0.00%)
After hours: 4:48PM EST

Stock chart is not supported by your current browser
Previous Close26.10
Open26.59
Bid26.98 x 1300
Ask27.75 x 1100
Day's Range26.34 - 27.90
52 Week Range11.31 - 31.58
Volume1,772,696
Avg. Volume959,270
Market Cap2.087B
Beta (3Y Monthly)3.69
PE Ratio (TTM)N/A
EPS (TTM)-3.88
Earnings DateFeb 22, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.70
Trade prices are not sourced from all markets
  • Insmed to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call on Friday, February 22, 2019
    PR Newswire11 hours ago

    Insmed to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call on Friday, February 22, 2019

    BRIDGEWATER, N.J. , Feb. 15, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that ...

  • Is Insmed Incorporated’s (NASDAQ:INSM) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.2 days ago

    Is Insmed Incorporated’s (NASDAQ:INSM) Balance Sheet Strong Enough To Weather A Storm?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Small-cap and large-cap companies receive a lotRead More...

  • Markit7 days ago

    See what the IHS Markit Score report has to say about Insmed Inc.

    Insmed Inc NASDAQ/NGS:INSMView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for INSM with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding INSM totaled $3.07 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire8 days ago

    Market Trends Toward New Normal in lululemon athletica inc, Insmed, Advanced Disposal Services, AGCO, Douglas Dynamics, and Ballard Power — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Feb. 07, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PR Newswire11 days ago

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., Feb. 4, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commencement of their employment, the employees received options on February 1, 2019 to purchase an aggregate 35,680 shares of Insmed common stock at an exercise price of $24.41 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

  • Options Traders Expect Huge Moves in Insmed (INSM) Stock
    Zacks21 days ago

    Options Traders Expect Huge Moves in Insmed (INSM) Stock

    Investors need to pay close attention to Insmed (INSM) stock based on the movements in the options market lately.

  • Benzingalast month

    Top 5 Small-Cap Winners And Losers, Week Of Jan. 7

    In today’s round-up of the previous week’s top five shakers and fakers (i.e. winners and losers,), we see some major jumps or drops depending on how well company announcements were received. For some, ...

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Foollast month

    3 Biotech Stocks That Soared This Week: Are They Buys?

    These biotech stocks jumped 31% or more over the last few days. Can their momentum continue?

  • The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference
    Motley Foollast month

    The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference

    These companies arguably stole the show at J.P. Morgan's high-profile healthcare conference this year.

  • Here's Why Insmed Rocketed 43% Higher on Monday
    Motley Foollast month

    Here's Why Insmed Rocketed 43% Higher on Monday

    Investors are impressed with early sales numbers for the biotech's Arikayce antibiotic.

  • ETF Trendslast month

    Biotech ETFs Surge After Eli Lilly Buys Out Loxo Oncology

    Biotechnology stocks and sector-related ETFs were among the best performers Monday after Eli Lilly (NYSE: LLY) said it will acquire Loxo Oncology Inc. (NasdaqGS: LOXO) for $8 billion. Among the best performers ...

  • MarketWatchlast month

    Insmed stock shoots up 18% after company says it expects drug Arikayce to bring in $9.8 million in fourth quarter

    Shares of Insmed Incorporated shot up 18% in after-hours trading Friday after the company announced it expected sales of its antibacterial Arikayce to be $9.8 million for the fourth quarter, with $9.2 million in U.S. sales and $600,000 in sales outside the U.S. The drug is used to treat patients with a lung disease caused by a group of bacteria called Mycobacterium avium complex (MAC) and who do not respond to traditional treatment. Arikayce was granted accelerated approval by the FDA in September. Insmed said more than 500 U.S. patients had started treatment with the drug and approximately 600 physicians had written at least one prescription for the therapy as of Dec. 31. Shares of Insmed have fallen 51% in the past 12 months, while the iShares NASDAQ Biotech ETF has fallen 6.75%. The S&P 500 has fallen 7%.

  • Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch and Outlines Strategic Priorities for 2019
    PR Newswirelast month

    Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch and Outlines Strategic Priorities for 2019

    BRIDGEWATER, N.J., Jan. 4, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the U.S. launch of ARIKAYCE® (amikacin liposome inhalation suspension), including preliminary unaudited net product sales for the fourth quarter of 2018, and shared the Company's strategic priorities for 2019. ARIKAYCE was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on September 28, 2018, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options.

  • Is Insmed Incorporated (INSM) A Good Stock To Buy?
    Insider Monkey2 months ago

    Is Insmed Incorporated (INSM) A Good Stock To Buy?

    Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don’t publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That’s why we analyze the […]

  • ACCESSWIRE3 months ago

    Healthcare Stocks with Turnaround Potential

    HENDERSON, NV / ACCESSWIRE / November 14, 2018 / After a tough year, the prospect that a split congress could be a good thing for healthcare stocks is causing some investors to look again at several smaller ...